The Changing Landscape of Substance Use Disorders

Lowe DJE, Sasiadek JD, Coles AS, et al.: Cannabis and mental illness: a review. Eur Arch Psychiatry Clin Neurosci 2019; 269:107–120Crossref, Google Scholar

Nielsen S, Gowing L, Sabioni P, et al.: Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2019; 1:CD008940Google Scholar

Sullivan MA, Bisaga A, Pavlicova M, et al.: A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry 2019; 176:129–137Crossref, Google Scholar

Uhl GR, Koob GF, Cable J: The neurobiology of addiction. Ann N Y Acad Sci 2019Crossref, Google Scholar

Vermeulen J, Schirmbeck F, Blankers M, et al.: Smoking, symptoms, and quality of life in patients with psychosis, siblings, and healthy controls: a prospective, longitudinal cohort study. Lancet Psychiatry 2019; 6:25–34Crossref, Google Scholar

Brezing CA, Levin FR: The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology 2018; 43:173–194Crossref, Google Scholar

Crescenzo F, Ciabattini M, Cipriani A et al.. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. PLoS Med. 2018 Dec 26;15(12):e1002715.Crossref, Google Scholar

Deng H, Verrico CD, Kosten TR, et al.: Psychosis and synthetic cannabinoids. Psychiatry Res 2018; 268:400–412Crossref, Google Scholar

Farahzadi MH, Moazen-Zadeh E, Razaghi E, et al.: Riluzole for treatment of men with methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2018; 33:305–315Crossref, Google Scholar

Hurt RT, Ebbert JO, Croghan IT, et al.: Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: a randomized controlled trial. Drug Alcohol Depend 2018; 184:12–17Crossref, Google Scholar

Larochelle MR, Bernson D, Land T, et al.: Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med 2018; 169:137–145Crossref, Google Scholar

Lee JD, Nunes EV Jr, Novo P, et al.: Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:309–318Crossref, Google Scholar

Reus VI, Fochtmann LJ, Bukstein O, et al: The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry 2018; 175:86–90Google Scholar

Sabioni P, Le Foll B: Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. F1000 Res 2018; 7:173Google Scholar

Scott JC, Slomiak ST, Jones JD, et al.: Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry 2018; 75:585–595Crossref, Google Scholar

Volkow ND, Jones EB, Einstein EB, et al.: Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry 2019; 76:208–216Crossref, Google Scholar

Zehra A, Burns J, Liu CK, et al: Cannabis addiction and the brain: a review. J Neuroimmune Pharmacol 2018; 13:438–452Google Scholar

Bahorik AL, Leibowitz A, Sterling SA, et al.: Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord 2017; 213:168–171Crossref, Google Scholar

Carroll KM, Kiluk BD: Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again. Psychol Addict Behav 2017; 31:847–861Crossref, Google Scholar

Carroll KM, Weiss RD: The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry 2017; 174:738–747Google Scholar

Hassan AN, Howe AS, Samokhvalov AV, et al.: Management of mood and anxiety disorders in patients receiving opioid agonist therapy: review and meta-analysis. Am J Addict 2017; 26:551–563Crossref, Google Scholar

Hser YI, Huang D, Saxon AJ, et al.: Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine+naloxone and methadone. J Addict Med 2017; 11:63–69Crossref, Google Scholar

Klaman SL, Isaacs K, Leopold A, et al.: Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. J Addict Med 2017; 11:178–190Crossref, Google Scholar

Sordo L, Barrio G, Bravo MJ, et al.: Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; 357:j1550Crossref, Google Scholar

Webster LR: Risk factors for opioid-use disorder and overdose. Anesth Analg 2017; 125:1741–1748Crossref, Google Scholar

Blanco C, Rafful C, Wall MM, et al.: Towards a comprehensive developmental model of cannabis use disorders. Addiction 2014; 109:284–294Crossref, Google Scholar

Gates PJ, Sabioni P, Copeland J, et al.: Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 2016; (5):CD005336Google Scholar

Humphreys K, Blodgett JC, Wagner TH: Estimating the efficacy of Alcoholics Anonymous without self-selection bias: an instrumental variables re-analysis of randomized clinical trials. Alcohol Clin Exp Res 2014; 38:2688–2694Crossref, Google Scholar

Tang YY, Tang R, Posner MI: Mindfulness meditation improves emotion regulation and reduces drug abuse. Drug Alcohol Depend 2016; 163(Suppl 1):S13–S18 [Review]Crossref, Google Scholar

Yuodelis-Flores C, Ries RK: Addiction and suicide: a review. Am J Addict 2015; 24:98–104Google Scholar

Zulauf CA, Sprich SE, Safren SA, et al.: The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep 2014; 16:436Crossref, Google Scholar